Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,145.03 USD
-5.16 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1,150.00 +4.97 (0.43%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Income Statements
Fiscal Year end for Regeneron Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 13,117 | 12,173 | 16,072 | 8,497 | 7,863 |
Cost Of Goods | 1,816 | 1,560 | 2,438 | 1,120 | 782 |
Gross Profit | 11,301 | 10,613 | 13,634 | 7,377 | 7,081 |
Selling & Adminstrative & Depr. & Amort Expenses | 7,254 | 5,874 | 4,687 | 3,801 | 4,871 |
Income After Depreciation & Amortization | 4,047 | 4,739 | 8,947 | 3,577 | 2,210 |
Non-Operating Income | 225 | 179 | 436 | 291 | 250 |
Interest Expense | 73 | 59 | 57 | 57 | 30 |
Pretax Income | 4,199 | 4,859 | 9,326 | 3,810 | 2,429 |
Income Taxes | 246 | 520 | 1,251 | 297 | 313 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 3,954 | 4,338 | 8,075 | 3,513 | 2,116 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 3,954 | 4,338 | 8,075 | 3,513 | 2,116 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 4,468 | 5,080 | 9,233 | 3,813 | 2,420 |
Depreciation & Amortization (Cash Flow) | 421 | 341 | 286 | 236 | 210 |
Income After Depreciation & Amortization | 4,047 | 4,739 | 8,947 | 3,577 | 2,210 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 113.70 | 113.50 | 112.20 | 115.10 | 114.60 |
Diluted EPS Before Non-Recurring Items | 37.66 | 40.11 | 74.66 | 28.66 | 21.47 |
Diluted Net EPS (GAAP) | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 |
Fiscal Year end for Regeneron Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3,547.10 | 3,145.00 | 3,434.30 | 3,362.70 | 3,158.10 |
Cost Of Goods | 480.20 | 433.80 | 517.00 | 436.40 | 404.90 |
Gross Profit | 3,066.90 | 2,711.20 | 2,917.30 | 2,926.30 | 2,753.20 |
SG&A, R&D, and Dept/Amort Expenses | 1,997.30 | 1,959.80 | 1,944.40 | 1,815.30 | 1,736.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1,069.60 | 751.40 | 972.90 | 1,111.00 | 1,016.50 |
Non-Operating Income | 573.30 | -34.60 | 193.00 | 17.60 | 85.30 |
Interest Expense | 14.80 | 16.10 | 18.30 | 17.80 | 18.90 |
Pretax Income | 1,628.10 | 700.70 | 1,147.60 | 1,110.80 | 1,082.90 |
Income Taxes | 195.80 | -21.30 | -12.00 | 103.00 | 114.50 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 1,432.30 | 722.00 | 1,159.60 | 1,007.80 | 968.40 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 1,432.30 | 722.00 | 1,159.60 | 1,007.80 | 968.40 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 115.40 | 115.10 | 113.80 | 113.40 | 113.90 |
Diluted EPS Before Non-Recurring Items | 10.10 | 7.97 | 10.18 | 10.17 | 8.79 |
Diluted Net EPS (GAAP) | 12.41 | 6.27 | 10.21 | 8.89 | 8.50 |